Table II.

Eosinophil responses related to COVID-19

Issue	Likely significance
Atopy-related eosinophilia	Atopy does not appear to have an exacerbating role in COVID-19
Eosinophil antiviral activity	The antiviral activity of eosinophils is unlikely involved in COVID-19 because the antiviral activity of eosinophils has not yet been observed in humans
Biological drug–induced eosinopenia	There are no data to date substantiating any risk for infections following depletion of eosinophils
COVID-19–associated eosinopenia	The eosinopenia associated with COVID-19 is likely a secondary phenomenon and not directly contributing to the disease course
Lung eosinophilia associated with immunopotentiation by SARS vaccines	Vaccine candidates must demonstrate the absence of eosinophil-associated disease enhancement before widespread deployment